Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C11H14N2S2 |
| Molecular Weight | 238.372 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=S)C1(CCCS1)C2=NC=CC=C2
InChI
InChIKey=ITNLONMDUMHEOK-UHFFFAOYSA-N
InChI=1S/C11H14N2S2/c1-12-10(14)11(6-4-8-15-11)9-5-2-3-7-13-9/h2-3,5,7H,4,6,8H2,1H3,(H,12,14)
Picartamide had potent antisecretory and antiulcerogenic effects which were, at least, 10 times more pronounced than those of cimetidine. The mechanism of action of picartamide has not yet been determined but it seems that an anticholinergic or an H2 receptor antagonist effect should be excluded. The results show that picartamide is also active on the pure vagus-stimulated gastric acid secretion. The lack of effect upon gastric pepsin and plasma PP suggests that picartamide is not likely to act on the basolateral cholinergic receptor and that it affects further cellular steps involved in hydrogen ion secretion.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Long-term efficacy and tolerability of omeprazole in 20 patients with severe Zollinger-Ellison syndrome]. | 1989-08-01 |
|
| Synthesis and antisecretory and antiulcer activities of derivatives and analogues of 2-(2-pyridyl)tetrahydrothiophene-2-carbothioamide. | 1987-01 |
|
| Effect of 40749 RP on basal and sham feeding stimulated gastric secretion in man. | 1987 |
|
| [Treatment of gastric acid hypersecretion in the Zollinger-Ellison syndrome with a thioamide derivative (40749 RP). Comparison with ranitidine]. | 1986-06-01 |
|
| Acute and chronic 24-hour gastric pH and pharmacokinetic studies with a long acting antisecretory drug (40749 RP) in peptic ulcer. | 1986-05 |
|
| Effects of single daily doses of a pyridil-2-tetrahydrothiophene derivative (40749 RP) on 24 hour H+ activity, nocturnal acid output, gastrin and pepsinogen I profiles in duodenal ulcer patients. | 1986-04 |
|
| Increased effect of multiple doses of 40 749 RP a new long acting gastric antisecretory agent. | 1986 |
|
| A new H+ suppressor: RP 40 749 versus placebo and cimetidine. Ambulatory 48-hour intragastric pH monitoring in normal men. | 1985-10 |
|
| The antisecretory effects of RP 40 749 in patients with previous duodenal ulcer. | 1985-10 |
|
| Influence of RP 40749 on basal and meal-stimulated serum-gastrin, serum-pepsinogen I, and gastrin-content of the antral mucosa in duodenal ulcer patients. | 1985-07 |
|
| Inhibition of histalog-stimulated gastric secretion by 40 749 RP, a new long-acting gastric antisecretory agent. | 1985 |
|
| RP 40749 in treatment of duodenal ulcer. | 1984-04-07 |
|
| [Efficacy of a new antisecretory agent (40 749 RP) on human gastric secretion induced by a meal (intragastric titration)]. | 1984-04 |
|
| [Inhibition by a 2-pyridyltetrahydrothiophene derivative (40749 RP) of gastric secretion stimulated by pentagastrin. Results in 30 duodenal ulcer patients]. | 1984-02 |
|
| Inhibition of pentagastrin-stimulated gastric secretion by pyridyl-2-tetrahydrothiophene derivative (RP 40749) | 1982-05-22 |
|
| [Antisecretory and antiulcer activities of N-methyl-2-(2-pyridyl)-2,3,4,5,-tetrahydro-2-thiophene-carbothioamide (R.P. .40, 749) (author's transl)]. | 1982-03-22 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3123255
A single dose of 2 mg/kg
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29723
Created by
admin on Mon Mar 31 17:57:32 GMT 2025 , Edited by admin on Mon Mar 31 17:57:32 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7JZ930H2M6
Created by
admin on Mon Mar 31 17:57:32 GMT 2025 , Edited by admin on Mon Mar 31 17:57:32 GMT 2025
|
PRIMARY | |||
|
76732-75-7
Created by
admin on Mon Mar 31 17:57:32 GMT 2025 , Edited by admin on Mon Mar 31 17:57:32 GMT 2025
|
PRIMARY | |||
|
DTXSID30868413
Created by
admin on Mon Mar 31 17:57:32 GMT 2025 , Edited by admin on Mon Mar 31 17:57:32 GMT 2025
|
PRIMARY | |||
|
100000082452
Created by
admin on Mon Mar 31 17:57:32 GMT 2025 , Edited by admin on Mon Mar 31 17:57:32 GMT 2025
|
PRIMARY | |||
|
CHEMBL100424
Created by
admin on Mon Mar 31 17:57:32 GMT 2025 , Edited by admin on Mon Mar 31 17:57:32 GMT 2025
|
PRIMARY | |||
|
C66380
Created by
admin on Mon Mar 31 17:57:32 GMT 2025 , Edited by admin on Mon Mar 31 17:57:32 GMT 2025
|
PRIMARY | |||
|
278-531-4
Created by
admin on Mon Mar 31 17:57:32 GMT 2025 , Edited by admin on Mon Mar 31 17:57:32 GMT 2025
|
PRIMARY | |||
|
5295
Created by
admin on Mon Mar 31 17:57:32 GMT 2025 , Edited by admin on Mon Mar 31 17:57:32 GMT 2025
|
PRIMARY | |||
|
SUB09807MIG
Created by
admin on Mon Mar 31 17:57:32 GMT 2025 , Edited by admin on Mon Mar 31 17:57:32 GMT 2025
|
PRIMARY | |||
|
3034005
Created by
admin on Mon Mar 31 17:57:32 GMT 2025 , Edited by admin on Mon Mar 31 17:57:32 GMT 2025
|
PRIMARY |
ACTIVE MOIETY